Drugs /

plerixafor

Back to Drugs List

Overview

NCI Definition [1]:
A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.

Clinical Trials

View Clinical Trials for plerixafor

Plerixafor has been investigated in 7 clinical trials, of which 4 are open and 3 are closed. Of the trials investigating plerixafor, 3 are phase 1 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open).

CTAG1A Expression, CTAG1B Expression, and CTAG1B Overexpression are the most frequent biomarker inclusion criteria for plerixafor clinical trials.

Multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia are the most common diseases being investigated in plerixafor clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Plerixafor
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Plerixafor
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating plerixafor and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lm-3100, 1,1'-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, jm-3100, bis(tetraazacyclotetradecane) derivative, amd 3100, mozobil, plerixafor, plerixafor, plerixafor (substance), mozobil, amd3100, sdz sid 791, 1,1'-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, jm 3100, plerixafor (product), amd-3100, jm3100
Drug Target(s) [2]:
CXCR4
NCIT ID [1]:
C1777
SNOMED ID [1]:
C-7A007

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.